share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

SEC announcement ·  Jun 25 05:36
Summary by Futu AI
CRISPR Therapeutics COO Julianne Bruno sold 3,366 shares of the company's common stock on 06/21/2024, as per the latest SEC filings. The shares were sold at a price of $56.09 each, totaling approximately $188,798.94. This transaction followed an acquisition of 7,000 shares on 06/20/2024 through the exercise of derivative securities. After these transactions, Bruno directly holds 6,745 shares of CRISPR Therapeutics. Additionally, Bruno has an indirect beneficial ownership of 7,088 shares through The Julianne Bruno 2022 GRAT. The transactions have been reported as completed.
CRISPR Therapeutics COO Julianne Bruno sold 3,366 shares of the company's common stock on 06/21/2024, as per the latest SEC filings. The shares were sold at a price of $56.09 each, totaling approximately $188,798.94. This transaction followed an acquisition of 7,000 shares on 06/20/2024 through the exercise of derivative securities. After these transactions, Bruno directly holds 6,745 shares of CRISPR Therapeutics. Additionally, Bruno has an indirect beneficial ownership of 7,088 shares through The Julianne Bruno 2022 GRAT. The transactions have been reported as completed.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.